Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$269.78 USD

269.78
524,640

+5.44 (2.06%)

Updated May 14, 2024 04:00 PM ET

After-Market: $268.29 -1.49 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for UTHR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

United Therapeutics Corporation [UTHR]

Reports for Purchase

Showing records 541 - 560 ( 587 total )

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 541

11/18/2011

Company Report

Pages: 7

EU Regulatory Progress Offsets Beraprost-MR Program Suspension. Reiterate OUTPERFORM and $87 Fair Value

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 542

11/10/2011

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 543

10/28/2011

Company Report

Pages: 5

3Q11 Results Review: Solid Quarter as Revenues top Expectations

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 544

10/27/2011

Company Report

Pages: 9

As in Q2, Q3 Beat With Strong Product Sales.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 545

10/24/2011

Company Report

Pages: 11

Q3 Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 546

10/18/2011

Company Report

Pages: 6

Model Update for $250MM Convertible Senior Notes Offering and $212MM Share Repurchase. FV Goes to $87. Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 547

10/10/2011

Industry Report

Pages: 21

Q4 2011 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 548

08/25/2011

Company Report

Pages: 5

FREEDOM-C2 Fails To Hit Primary Endpoint; Downgrading to Hold and Reducing PT

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 549

08/24/2011

Company Report

Pages: 7

FREEDOM-C2 Failed; We View Regulatory Risk as High. Due to Failure

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 550

08/16/2011

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 551

08/05/2011

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of August 7

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 552

07/29/2011

Company Report

Pages: 5

2Q11 Results Review: Tyvaso and Adcirca Ramp; FREEDOMC2 Results on Track for Late August Read Out

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 553

07/28/2011

Company Report

Pages: 10

Q2 Beat With Strong Product Sales. We Believe UTHR Is At An Attractive Valuation

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 554

07/26/2011

Company Report

Pages: 9

Q2 Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 555

06/07/2011

Company Report

Pages: 5

FREEDOM-M Results Are Good, But Fall Short of High Expectations; Still an Effective Agent

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 556

06/06/2011

Company Report

Pages: 8

We Believe FREEDOM-m Results Are More Positive Than At First Glance.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 557

05/16/2011

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 558

05/09/2011

Company Report

Pages: 8

Preview of UTHR Presentations at the American Thoracic Society (ATS) International Conference.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 559

04/29/2011

Company Report

Pages: 5

We are assuming coverage with a Buy rating and a $90 price target

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 560

04/28/2011

Company Report

Pages: 9

Q1 Missed But Growth Intact and We See Significant Upside From Near-Term Data. Raising Rating to OUTPERFORM from NEUTRAL and FV to $94 from $79

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party